Pharmacokinetics of clindamycin in obese and nonobese children

Michael J. Smith*, Daniel Gonzalez, Jennifer L. Goldman, Ram Yogev, Janice E. Sullivan, Michael D. Reed, Ravinder Anand, Karen Martz, Katherine Berezny, Daniel K. Benjamin, P. Brian Smith, Michael Cohen-Wolkowiez, Kevin Watt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Although obesity is prevalent among children in the United States, pharmacokinetic (PK) data for obese children are limited. Clindamycin is a commonly used antibiotic that may require dose adjustment in obese children due to its lipophilic properties. We performed a clindamycin population PK analysis using data from three separate trials. A total of 420 samples from 220 children, 76 of whom had a body mass index greater than or equal to the 95th percentile for age, were included in the analysis. Compared to other metrics, total body weight (TBW) was the most robust measure of body size. The final model included TBW and a sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL (liters/hour) = 13.8 × (TBW/70)0.75 × [PMA2.83/(39.52.83+PMA2.83)]; volume of distribution (V) was associated with TBW, albumin (ALB), and alpha-1 acid glycoprotein (AAG): V (liters) = 63.6 × (TBW/70) × (ALB/3.3)0.83 × (AAG/2.4)0.25. After accounting for differences in TBW, obesity status did not explain additional interindividual variability in model parameters. Our findings support TBW-based dosing for obese and nonobese children.

Original languageEnglish (US)
Article numbere02014-16
JournalAntimicrobial agents and chemotherapy
Issue number4
StatePublished - Apr 2017


  • Antibiotics
  • Children
  • Clindamycin
  • Obesity
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology


Dive into the research topics of 'Pharmacokinetics of clindamycin in obese and nonobese children'. Together they form a unique fingerprint.

Cite this